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Abstract 
Purpose: To report ultraviolet-A (UV-A) light treatment in a patient with Acanthamoeba 
keratitis (AK).  
Methods: Interventional case report. A standard protocol for ultraviolet corneal therapy, 
with a power emission of 3 mW/cm2 and a wavelength of 370 nm, was used. The protocol 
included an 8-nm bandwidth at a 54-mm distance measured with a collimation system of 
diodes as well as a protective shield of riboflavin in a case of documented AK.  
Results: A 54-year-old female patient with AK, showing no therapeutic response to a 
wide variety of topical antimicrobial agents and with a visual acuity of 20/400, was 
treated with UV-A therapy. The patient displayed a favourable response in the first 24 h 
after treatment, with improvement of symptoms, visual acuity (to 20/200) and 
biomicroscopy cornea with haze degree I. By the third week post-treatment, the patient 
was symptom-free. Her visual acuity was 20/30, and the affected cornea was clear. Five 
months after treatment, there had been no recurrence, and her vision was 20/20.  
Conclusions: Treatment with UV-A light was an effective therapy in this case of AK. 
 
Introduction 
Since 1973, it has been recognised that Acanthamoeba may cause severe blinding 
keratitis. Early diagnosis and aggressive medical treatment using various combinations of 
specific antiprotozoal drugs has improved the possibility of successfully managing this 
corneal disease. However, penetrating keratoplasty may be found in cases that progress Case Rep Ophthalmol 2011;2:291–295 
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despite maximal medical therapy and these cases can show evidence of severe stromal 
melting with imminent perforation [1]. 
Numerous studies demonstrate the efficacy of ultraviolet (UV) light for the 
inactivation of many types of microorganism, including protozoa [2–5]. With this in 
mind, a case of Acanthamoeba keratitis (AK) treated with UV-A therapy is reported. 
Case Report 
A 54-year-old female with a history of soft contact lens use and nail scratch trauma in her right eye 
was referred to our hospital after approximately 8 weeks of failed intensive oral and topical empirical 
therapy for presumed bacterial keratitis. 
The patient reported severe pain, blepharospasm, photophobia, eye tearing and foreign body 
sensation. The visual acuity in her right eye was 20/400. The patient also suffered from hyperaemic 
conjunctiva and a large corneal paracentral epithelial defect (approximately 8 × 7 mm) with underlying 
dense anterior stromal infiltrate not involving the visual axis (fig. 1). Right-eye intraocular pressure was 
12 mm Hg, with a normal posterior segment. In the left eye, the vision was 20/20, and the anterior and 
posterior segments were normal. Previous topical antimicrobial therapy was stopped for 24 h, and right 
corneal scraps were sent for new bacterial and fungal cultures. Negative Gram stain and cultures at 24, 
48, and 72 h of incubation were reported. Anti-HSV-1 and 2 antibodies were also not detected. Corneal 
ulcer scrapings mounted on 10% potassium hydroxide revealed Acanthamoeba cysts, which coincided 
with a positive Acanthamoeba culture in Escherichia coli-enriched media. As an alternative to topical 
commercial treatment, which is not available in Mexico, the patient was offered corneal UV-A therapy 
and consented to this treatment. 
Our patient was treated using the standard protocol for UV corneal therapy. After topical 
anaesthesia of the cornea (with eye drops of 0.1% tetracaine every 5 min for 15 min), the epithelium was 
removed within a 9-mm diameter zone that included all corneal infiltrates. After inserting a lid 
speculum, 0.1% riboflavin (Ricrolin; Sooft, Italy) drops were administered every 2.5 min for 30 min. 
Afterwards, the cornea was irradiated for 30 min with 3 mW/cm
2 UV-A, at a wavelength of 370 nm, 
from a VEGA-CSO UV light device (Firenze, Italy); the light was placed at a distance of 54 mm from the 
eye and was measured with a collimation system of diodes (LED) (fig. 2). 
After the first 24 h, the outcome was favourable, with decreased symptoms, improved visual acuity 
(20/200) and a slit-lamp examination revealing partial resolution of the epithelial defect and stromal 
infiltrate with a mild corneal haze. At the third week after treatment, the patient’s best corrected visual 
acuity was 20/30, and anterior segment exploration of her right eye showed no hyperaemic conjunctiva, 
a minimally hazy epithelium, and a clear chamber (fig. 3). 
Discussion 
Acanthamoeba is a ubiquitous, free-living protozoan that can cause severe keratitis. 
The outcome of AK has improved significantly over recent years because of earlier 
diagnosis and the introduction of effective amoebicidal drugs. The main treatment 
includes a combination of three classes of drugs: diamidine derivatives, imidazole 
derivatives, and aminoglycosides (topical and oral). However, toxic keratopathy may 
develop at any time, and these drugs are not readily available in every country. Although 
acanthamoebic organisms can be eradicated from the cornea by medical therapy in a 
great number of cases, severe inflammation and necrosis may spread to the paracentral 
corneal stroma or into the peripheral cornea, and this is an indication of penetrating 
keratoplasty. However, the prognosis after keratoplasty is sometimes uncertain, and 
medical therapy should be continued for at least several months to ensure elimination of Case Rep Ophthalmol 2011;2:291–295 
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any residual Acanthamoeba cysts in the recipient tissue [1]. From this perspective, it is 
helpful to have another therapeutic option for treating infectious and melting keratitis 
that does not respond to broad-spectrum antibiotics. 
We hypothesised that corneal UV therapy was a viable option in this case, mainly 
because there are no available diamidine and imidazole derivatives in commercial eye 
drops in Mexico. Soon after UV-A cross-linking treatment in our patient, the symptoms 
improved; the epithelial defects healed; and the infiltrate was smaller. UV-A therapy was 
effective for inactivation of AK by increasing resistance against enzymatic digestion and 
because of its inherent antimicrobial power. 
First, UV light (wavelength 320–400 nm) permanently cross-links helical regions of 
DNA and RNA, inactivating a broad range of viruses, bacteria and protozoa. An 
inactivation level of 93.7% of some protozoan cysts, from species such as Giardia lamblia 
and Cryptosporidium hominis, has been demonstrated with a UV dose range of 3 to 40 
mJ/cm
2 [2, 3]. Riboflavin easily diffuses into the stroma once the epithelial barrier has 
been broken, and Acanthamoeba cysts are killed as deep as 250–300 μm inside the stroma. 
Microbes located in the interface, which is usually located <200 μm deep, can be killed by 
the same process via the free radicals produced during cross-linking interfering with the 
microbial cell wall [4, 5]. 
Second, Spoerl et al. [6] found that cross-linking the cornea by using riboflavin and 
UV-A increases collagen resistance to digesting enzymes. Additionally, there are other 
reports that, like ours, describe a favourable outcome in AK treated with UV light and 
riboflavine [7]. 
For these reasons, we believe that UV-A therapy should be studied as an alternative 
treatment for selected cases of AK. 
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Fig. 1. Ulcerative Acanthamoeba keratitis defect prior to UV-riboflavin therapy. 
 
 
 
Fig. 2. Device used for the UV therapy. 
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Fig. 3. Right-eye corneal appearance 3 weeks after treatment, showing resolution of keratitis. 
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